HRMY vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HRMY presents a dichotomy between a rock-solid balance sheet and deteriorating earnings performance. The Piotroski F-Score of 4/9 indicates stable financial health, supported by an exceptionally low Debt/Equity ratio (0.19) and strong liquidity (Current Ratio 3.60). However, these strengths are offset by a severe -55% YoY earnings contraction and a bearish insider sentiment characterized by C-suite selling. While the stock trades near its Graham Number ($30.21) and boasts an attractive Forward P/E of 4.99, the disconnect between analyst targets ($42.00) and current growth trends suggests significant volatility ahead.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
HRMY vs LLY: Head-to-Head Comparison
This page compares Harmony Biosciences Holdings, Inc. (HRMY) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.